The FreMon Scientific Board of Directors wishes to introduce Dr. David P. Wellis. David takes the CEO position at FMS as a highly regarded CEO in the cell and gene and blood banking space. We also wish to thank Dr. Farideh Bischoff for her past service to the Company. Welcome David!
— Frederick Thacher
Co-founder, Chairperson
Co-founder, Chairperson
All,
I’m thrilled to join FreMon Scientific! Over a decade ago, I had the privilege of meeting co-founders Fred and Moni at the San Diego Blood Bank, where I was serving as CEO. Even then, I recognized the groundbreaking potential of ZipThaw. It’s remarkable to see how far this technology has advanced.
Momentum is building, but plenty of work remains to solidify ZipThaw as the gold standard in precision thawing for life-saving therapies. What excites me most is the strong position the business holds today.
While I’m not one to boast about myself, here’s a recent biographical sketch.
David is a strategic C-level leader with years of experience in startups, publicly traded life science companies and for not-for-profit healthcare. He has expertise in both blood banking and biotherapies, including CDMO services and antibody and cell therapeutic discovery and drug development and highly regulated healthcare operations. His career spans organizations that provide FDA-regulated services and commercialized cell therapy products.
David has a B.S. from
UC Irvine, an M.S. and Ph.D. from Emory University, postdoctoral training at Tufts University and UC Berkeley, and business training at Santa Clara University and UC Berkeley. He has held board and committee roles at the Blood Centers of America, National Institutes of Health, American Cancer Society, soon AABB (starting later this year) and several local biotechnology companies.
I’m excited to be a part of the FreMon Scientific family and eager to help drive this company to its full potential.
— David